To compare the capability to aid prediction of clinical outcome measures , including progression-free survival ( PFS ) and overall survival ( OS ) , between volumetric estimates from contrast material-enhanced ( CE ) T1-weighted subtraction maps and traditional segmentation in a randomized multicenter clinical trial of recurrent glioblastoma ( GBM ) patients treated with bevacizumab .